EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers

Riccardo Gili iD, Paola Lovino Camerino, Luca Lalli, Elisa Bellini iD, Chiara Tagliaferri, Filippo Bruno Lanza, Stefania Vecchio, Simone Caprioli, Giorgio Peretti, Lucia Del Mastro, Filippo Marchi

The Laryngoscope · 2026-05 · 136 (5) · 2189-2198

DOI: 10.1002/lary.70334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 23.12.2025. Verfasst von Riccardo Gili und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Biomarkers, Tumor, Laryngeal Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Head and neck squamous cell carcinoma (HNSCC) lacks reliable prognostic circulating biomarkers, and the role of the immune system in its progression remains incompletely understood. This study aimed to evaluate the prognostic value of systemic inflammatory and immune biomarkers in surgically treated patients with primary oral cavity (OCSCC) or laryngeal squamous cell carcinoma (LSCC).

Methods

This retrospective single‐center study included 394 patients with OCSCC or LSCC who underwent surgery with curative intent. Preoperative blood samples were analyzed to assess platelet, neutrophil, lymphocyte, and monocyte counts, as well as T‐cell subpopulations (CD3+, CD4+, and CD8+). Composite ratios—including neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), lymphocyte‐to‐monocyte ratio (LMR), and systemic immune‐inflammation index (SII)—were evaluated for their correlation with global (GR), local (LR), and distant (DR) recurrence risk.

Results

Univariate analysis identified elevated platelet counts, PLR, SII, and neutrophil levels as significantly associated with increased GR ( p = 0.0001, p = 0.0014, p = 0.0058 and p = 0.016, respectively) and LR risk, with the exception of neutrophil levels ( p = 0.0002, p = 0.0008, p = 0.0072, respectively). In contrast, higher CD4+/CD3+ ( p = 0.038) and CD4+/CD8+ ( p = 0.045) ratios were associated with reduced DR risk. Multivariate analysis confirmed platelet count as an independent predictor for GR ( p = 0.0001) and LR ( p = 0.0002), while a high CD4+/CD8+ ratio ( p = 0.045) was independently protective against DR.

Conclusion

These findings highlight the prognostic relevance of platelet‐related inflammatory markers and circulating T‐cell ratios in recurrence risk among HNSCC patients. The differential associations with local versus distant recurrence underscore the complex interplay between systemic inflammation and adaptive immunity. Prospective validation is warranted to confirm these biomarkers' utility. Level of Evidence 4.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorLaryngeal NeoplasmsMouth NeoplasmsHead and Neck NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPrognosisAdultNeutrophilsPredictive Value of TestsInflammationPlatelet CountAged, 80 and overLymphocyte Count

Stichwörter der Autor:innen

biomarkershead and neck squamous cell carcinomainflammatoryrecurrence

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Medical Oncology, Department of Internal Medicine and Medical Specialties, University of Genova, Genoa, Italy.
  • Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Unit of Otorhinolaryngology-Head and Neck Surgery, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genova, Genoa, Italy.
  • Unit of Translational Immunology, IRCCS Foundation National Cancer Institute, Milan, Italy.
  • Radiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

ORCID-Profile: Riccardo Gili, Elisa Bellini

Zitieren

APA

Gili, R., Camerino, P. L., Lalli, L., Bellini, E., Tagliaferri, C., Lanza, F. B., Vecchio, S., Caprioli, S., Peretti, G., Del Mastro, L., & Marchi, F. (2026). Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers. The Laryngoscope, 136(5), 2189-2198. https://doi.org/10.1002/lary.70334

Vancouver

Gili R, Camerino PL, Lalli L, Bellini E, Tagliaferri C, Lanza FB, et al. Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers. The Laryngoscope. 2026;136(5):2189-2198. doi:10.1002/lary.70334

BibTeX
@article{Gili2026,
  author = {Gili, Riccardo and Camerino, Paola Lovino and Lalli, Luca and Bellini, Elisa and Tagliaferri, Chiara and Lanza, Filippo Bruno and Vecchio, Stefania and Caprioli, Simone and Peretti, Giorgio and Del Mastro, Lucia and Marchi, Filippo},
  title = {Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers},
  journal = {The Laryngoscope},
  year = {2026},
  volume = {136},
  number = {5},
  pages = {2189--2198},
  doi = {10.1002/lary.70334}
}
Kostenlos starten →